Pharma BD Deal Intelligence
Cephalon to acquire Group Lafon for $450 million cash, gaining worldwide rights to Provigil and lowering cost of goods sold; the company framed the deal as…
Sleep Foundation reports ~200,000 Americans have narcolepsy with <50,000 diagnosed; modafinil/armodafinil remain first-line for excessive daytime sleepiness.
Modafinil/Provigil became Cephalon's flagship product post-Lafon acquisition; pre-genericization peak sales exceeded $800M annually before generics in 2012.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon announced agreement Dec 2000 to acquire France's Group Lafon for $450M cash, securing worldwide modafinil (Provigil) rights and the API manufacturing site (Mitry-Mory). Closed in December 2001 after share-purchase amendment.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) (this deal) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2000 deals · Cephalon Inc. deals · Neurology deals